Bispecific binding agents binding to CLDN18.2 and CD3

The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Saved in:
Bibliographic Details
Main Authors Bernett, Matthew, Moore, Gregory, Nisthal, Alex
Format Patent
LanguageEnglish
Published 29.08.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

Abstract The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
AbstractList The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Author Nisthal, Alex
Moore, Gregory
Bernett, Matthew
Author_xml – fullname: Bernett, Matthew
– fullname: Moore, Gregory
– fullname: Nisthal, Alex
BookMark eNrjYmDJy89L5WQwdcosLkhNzkzLTFZIysxLycxLV0hMT80rKYZzS_IVnH1c_Awt9IwUEvNSFJxdjHkYWNMSc4pTeaE0N4Oim2uIs4duakF-fGpxQWJyal5qSXxosKGhubGloYmpk5ExMWoAjYgszw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US11739145B2
GroupedDBID EVB
ID FETCH-epo_espacenet_US11739145B23
IEDL.DBID EVB
IngestDate Fri Jul 19 10:31:55 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US11739145B23
Notes Application Number: US202218062465
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230829&DB=EPODOC&CC=US&NR=11739145B2
ParticipantIDs epo_espacenet_US11739145B2
PublicationCentury 2000
PublicationDate 20230829
PublicationDateYYYYMMDD 2023-08-29
PublicationDate_xml – month: 08
  year: 2023
  text: 20230829
  day: 29
PublicationDecade 2020
PublicationYear 2023
RelatedCompanies Astellas Pharma Europe BV
Xencor, Inc
RelatedCompanies_xml – name: Astellas Pharma Europe BV
– name: Xencor, Inc
Score 3.4947634
Snippet The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title Bispecific binding agents binding to CLDN18.2 and CD3
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230829&DB=EPODOC&locale=&CC=US&NR=11739145B2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp6LzgwrSt2qbpB95KELTliGuG26VvY22a6B7aIet-O-blG7zRd_yAZfk4O6Su_tdAB4zPbeoQzItoSjRCKFIo5xwTV-ZOLcs27apBAqPI2sUk9eFuejBeouFaeuEfrfFEYVEZULem1Zfb_ZOLL_Nrayf00IMVS_h3PXV7nWMZPEVqvqeG0wn_oSpjLnxTI3eXcOwMTWI6Ql1fSCv0bLOfvDhSVTK5rdJCU_hcCqolc0Z9PJyAMds-_PaAI7GXcBbNDvZq8_B9AoJi5SpPUpatGAUJZHAqHrXbSqFvfmR4TwhJSlXCvPxBTyEwZyNNLH-cnfYZTzbbxVfQr-syvwKFGNlcUdHicVtwUoZruOI59hxeJalOibXMPybzvC_yRs4kYyTflJEb6HffH7ld8LQNul9y6EfotmAAw
link.rule.ids 230,309,786,891,25594,76903
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5KFetNq6L1FUFyiyabzWMPQcimoWqbFttKbyWvhXhIion4991d-vCit33A7O7AzDCPbxbgPtVzm7g41WKCYg1jgjTCMNP0zDJz23Ychwig8CiyB3P8srAWLfjYYGFkn9Bv2RyRS1TK5b2R-nq1C2IFsrayfkwKvlQ9hTMvUNfeMRLNV4ga-F5_Mg7GVKXUm0_V6M0zDMckBrZ8rq73HO4SSlfp3ReolNVvkxIewf6EUyubY2jlZRc6dPPzWhcORuuENx-uZa8-AcsvBCxSlPYoSSHBKEosgFH1dtpUCh0GkeE-ICUuM4UG5inchf0ZHWj8_OX2scv5dHdV8wzaZVXm56AYmc1cHcU2czgrRbqOIZabrsvSNNFNfAG9v-n0_tu8hc5gNhouh8_R6yUcCiaKmCkiV9BuPr_ya250m-RGcusHw7uC7Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Bispecific+binding+agents+binding+to+CLDN18.2+and+CD3&rft.inventor=Bernett%2C+Matthew&rft.inventor=Moore%2C+Gregory&rft.inventor=Nisthal%2C+Alex&rft.date=2023-08-29&rft.externalDBID=B2&rft.externalDocID=US11739145B2